Leukemia was allowed to establish in syngeneic immunocompetent C57BL/6 mice for three days, and then treatment with MRX2843, a highly specific small molecule MerTK tyrosine kinase inhibitor (MerTKI), was initiated via daily oral gavage at 60mg/kg – a dose that is known to inhibit MerTK in vivo, and has minimal toxic effects (21). Here, MERTK is linked to leukemia.